Bicalutamide | 毕卡鲁胺 | ICI 176334 | Androgen Receptor Inhibitor

首页 / / / 雄激素受体 / Bicalutamide/比卡鲁胺

Bicalutamide/比卡鲁胺 {[allProObj[0].p_purity_real_show]}

货号：A176397 同义名： 毕卡鲁胺 / ICI 176334; ZD 176334

Bicalutamide是一种口服活性、非甾体类雄激素受体（AR）拮抗剂，用于前列腺癌研究。

Bicalutamide/比卡鲁胺化学结构
CAS号：90357-06-5

Bicalutamide/比卡鲁胺 3D分子结构
CAS号：90357-06-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Bicalutamide/比卡鲁胺纯度/质量文件产品仅供科研

货号：A176397 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

雄激素受体亚型比较

产品名称	Androgen Receptor ↓ ↑	纯度
Cyproterone acetate	++++ Androgen Receptor, IC50: 7.1 nM	98%
Apalutamide	+++ Androgen Receptor, IC50: 16 nM	98%
AZD3514	+ Androgen Receptor, Ki: 2.2 μM	99%
Darolutamide	++++ Androgen receptor, Ki: 11 nM	98%
Flutamide	+++ Androgen Receptor, Ki: 55 nM	98%
Galeterone	++ Androgen Receptor, IC50: 384 nM	98%
Enzalutamide	+++ Androgen Receptor, IC50: 36 nM	98%
Megestrol	✔	98%
Spironolactone	++ Androgen Receptor, IC50: 77 nM	98+%
Bicalutamide	++ Androgen Receptor, IC50: 0.16 μM	99%
EPI-001	+ Androgen Receptor, IC50: ~6 μM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Bicalutamide/比卡鲁胺生物活性

靶点

Androgen Receptor

Androgen Receptor, IC50:0.16 μM

描述

The androgen receptor (AR) and the androgen-AR signaling pathway play a significant role in male sexual differentiation and the development and function of male reproductive and non-reproductive organs ^[7]. Bicalutamide is an AR antagonist with IC₅₀ of 0.16 μM in LNCaP/AR(cs) cell lines. In the setting of Castration-resistant prostate cancer (CRPC), bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity and prostate tumor cell growth. In addition, bicalutamide stimulate proliferation of VCaP cells in a dose-dependent manner. The therapeutic effect of bicalutamide (10 mg/kg/d) was conducted in castrate mice bearing LNCaP/AR(cs) xenograft tumors, the antitumor activity of bicalutamide in this model was largely restricted to growth inhibition rather than tumor shrinkage ^[8]. Notably, Single administration of bicalutamide reduced tumor growth by 79% at defined submaximal doses ^[9].

Bicalutamide/比卡鲁胺细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源
CHO-K1 cells		Function assay	2 h	Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, IC50=0.2 μM	20381361
COS1 cells		Function assay		Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, IC50=0.0869 μM	25646649
COS7 cells		Function assay		Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay, EC50=0.18 μM	22094279
CV1 cells		Function assay		Binding affinity to human androgen receptor expressed in CV1 cells, Ki=0.151 μM	17257838

Bicalutamide/比卡鲁胺动物研究

Dose

Rat: 10 mg/kg, 20 mg/kg^[3] (p.o.); 1 mg/kg - 250 mg/kg^[4] (p.o.) Nude mice: 150 mg/kg^[5] (p.o.), 50 mg/kg - 100 mg/kg^[6] (p.o.) Dog: 0.1 mg/kg - 100 mg/kg^[4] (p.o.); 0.25 mg/kg, 2.5 mg/kg^[4] (i.v.)

Administration

p.o.

Pharmacokinetics

Animal	Rats^[4]	Dogs^[4]
Dose	50 mg/kg (male)	2.5 mg/kg
Administration	p.o.	p.o. or i.v.
F	0.357	66.5 ± 4.0% (p.o.)
T_max	12 h	16.6 ± 12.7 h (p.o.)
t_1/2λ	18.6 h	5.49 ± 0.53 days (p.o.) 7.47 ± 0.90 days (i.v.)
CL		54.6 ± 9.2 μl/min/kg (i.v.)
C_max	15.4 μg/ml	2.44 ± 0.27 μg/ml (p.o.)
V_λ		0.852 ± 0.194 L/kg (i.v.)
AUC_∞	379 μg·h/ml	519 ± 34 μg·h/ml (p.o.) 796 ± 148 μg·h/ml (i.v.)

Bicalutamide/比卡鲁胺临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00298155	Cancer Prosta... 展开 >>te Neoplasms 收起 <<	Phase 2	Completed	-	United States, Washington ... 展开 >> Veterans' Administration Puget Sound Health Care System (VAPSHCS) Seattle, Washington, United States, 98108-1532 University of Washington Seattle, Washington, United States, 98195-6158 收起 <<
NCT00298155	-		Completed	-	-
NCT02064036	Adenocarcinoma of the Prostate	Not Applicable	Recruiting	October 2018	United States, California ... 展开 >> UC Davis Sacramento Cancer Center Dept of Radiation Oncology Recruiting Sacramento, California, United States, 95817 Contact: Richard Valicenti, MD 916-724-8295 rkvalicenti@ucdavis.edu Principal Investigator: Richard Valicenti, MD 收起 <<

Bicalutamide/比卡鲁胺参考文献

[1]The Protective Role Of Ascorbic Acid Administration On The Bicalutamide Induced Reduction In Semen Quality In The Sprague - Dawley Rat

[2]Cockshott ID, Plummer GF, et al. The pharmacokinetics of Casodex in laboratory animals. Xenobiotica. 1991 Oct;21(10):1347-55.

[3]Attar RM, Jure-Kunkel M, et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res. 2009 Aug 15;69(16):6522-30.

[4]Sirotnak FM, She Y, et al. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res. 2002 Dec;8(12):3870-6.

[5]Shukla GC, Plaga AR, Shankar E, Gupta S. Androgen receptor-related diseases: what do we know? Andrology. 2016 May;4(3):366-81. doi: 10.1111/andr.12167. Epub 2016 Mar 16. PMID: 26991422.

[6]Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. PMID: 22266222; PMCID: PMC3306502.

[7]Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18. PMID: 22614157; PMCID: PMC3582879.

Bicalutamide/比卡鲁胺实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.62mL

2.32mL

1.16mL

23.24mL

4.65mL

2.32mL

Bicalutamide/比卡鲁胺技术信息

CAS号	90357-06-5
分子式	C₁₈H₁₄F₄N₂O₄S
分子量	430.37
SMILES Code	O=C(NC1=CC=C(C#N)C(C(F)(F)F)=C1)C(C)(O)CS(=O)(C2=CC=C(F)C=C2)=O
MDL No.	MFCD00869971

别名	毕卡鲁胺 ;ICI 176334; ZD 176334; Abbreviation
运输	蓝冰
InChI Key	LKJPYSCBVHEWIU-UHFFFAOYSA-N
Pubchem ID	2375

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(116.18 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

Androgen Receptor

Androgen Receptor, IC50:0.16 μM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

CHO-K1 cells		Function assay	2 h	Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, IC50=0.2 μM	20381361
COS1 cells		Function assay		Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, IC50=0.0869 μM	25646649
COS7 cells		Function assay		Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay, EC50=0.18 μM	22094279
CV1 cells		Function assay		Binding affinity to human androgen receptor expressed in CV1 cells, Ki=0.151 μM	17257838
Freestyle293F cells		Function assay		Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, IC50=0.054 μM	23199477
HEK293 cells		Function assay	3 h	Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, IC50=54 nM	22391033
HeLa cells		Function assay		Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, IC50=0.14 μM	17804229
human 22Rv1 cells		Function assay	3 days	Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay, IC50=4.6 μM	24900588
human AU565 cell		Growth inhibition assay		Inhibition of human AU565 cell growth in a cell viability assay, IC50=19.7402 μM	SANGER
human BB49-HNC cell		Growth inhibition assay		Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=18.9532 μM	SANGER
human BFTC-905 cell		Growth inhibition assay		Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=17.4857 μM	SANGER
human CAMA-1 cell		Growth inhibition assay		Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=12.3926 μM	SANGER
human CAS-1 cell		Growth inhibition assay		Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=28.6294 μM	SANGER
human CCF-STTG1 cell		Growth inhibition assay		Inhibition of human CCF-STTG1 cell growth in a cell viability assay， IC50=4.92929 μM	SANGER
human CTB-1 cell		Growth inhibition assay		Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=24.5536 μM	SANGER
human DK-MG cell		Growth inhibition assay		Inhibition of human DK-MG cell growth in a cell viability assay, IC50=24.8917 μM	SANGER
human DU145 cells		Cytotoxic assay	72 h	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay, IC50=18 μM	SANGER
human ES5 cell		Growth inhibition assay		Inhibition of human ES5 cell growth in a cell viability assay, IC50=8.61154 μM	SANGER
human G-361 cell		Growth inhibition assay		Inhibition of human G-361 cell growth in a cell viability assay, IC50=17.826 μM	SANGER
human H4 cell		Growth inhibition assay		Inhibition of human H4 cell growth in a cell viability assay, IC50=26.9458 μM	SANGER
human HCC1954 cell		Growth inhibition assay		Inhibition of human HCC1954 cell growth in a cell viability assay, IC50=28.7525 μM	SANGER
human HT-3 cell		Growth inhibition assay		Inhibition of human HT-3 cell growth in a cell viability assay, IC50=0.73134 μM	SANGER
human KALS-1 cell		Growth inhibition assay		Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=19.6635 μM	SANGER
human KU-19-19 cell		Growth inhibition assay		Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=22.0242 μM	SANGER
human LB1047-RCC cell		Growth inhibition assay		Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=12.253 μM	SANGER
human LNCAP cells		Proliferation assay	3 days	Antiproliferative activity against human LNCAP cells after 3 days, IC50=0.7327 μM	26046313
human LNCAP cells		Cytotoxic assay	2 days	Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method, IC50=23.79 μM	23727044
human MCF7 cell		Growth inhibition assay		Inhibition of human MCF7 cell growth in a cell viability assay, IC50=39.301 μM	SANGER
human MDA-MB-453 cell		Growth inhibition assay		Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50=29.907 μM	SANGER
human MDA-MB-453 cells		Function assay		Displacement of [3H]R1881 from AR in human MDA-MB-453 cells, EC50=31 nM	23713567
human MDA-MB-453 cells		Function assay		Displacement of [3H]DHT from AR in human MDA-MB-453 cells, IC50=64 nM	20584610
human MKN45 cell		Growth inhibition assay		Inhibition of human MKN45 cell growth in a cell viability assay, IC50=6.9605 μM	SANGER
human NB6 cell		Growth inhibition assay		Inhibition of human NB6 cell growth in a cell viability assay, IC50=22.9135 μM	SANGER
human NCI-H187 cell		Growth inhibition assay		Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50=16.6616 μM	SANGER
human NCI-H2087 cell		Growth inhibition assay		Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50=21.0591 μM	SANGER
human NCI-H2228 cell		Growth inhibition assay		Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=13.7531 μM	SANGER
human NOS-1 cell		Growth inhibition assay		Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=11.2917 μM	SANGER
human OAW-42 cell		Growth inhibition assay		Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=28.7195 μM	SANGER
human PC-3 cell		Growth inhibition assay		Inhibition of human PC-3 cell growth in a cell viability assay, IC50=10.2791 μM	SANGER
human PC3 cells		Function assay		Displacement of [3H]R1881 from androgen receptor in human PC3 cells, EC50=4.3 μM	25591066
human PC3 cells	100　μM	Function assay	48 h	Inhibition of actin based pseudopodia formation in androgen-dependent human PC3 cells at 100 uM after 48 hrs by DAPI staining based fluorescence microscopy assay	22672984
human PC3 cells	0.1-1 μM	Function assay		Agonist activity at androgen receptor W741C mutant expressed in human PC3 cells assessed as stimulation of receptor transactivation at 0.1 to 1 uM by luciferase reporter gene assay	22175694
human RO82-W-1 cell		Growth inhibition assay		Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=23.1318 μM	SANGER
human RVH-421 cell		Growth inhibition assay		Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=21.5795 μM	SANGER
human SAS cell		Growth inhibition assay		Inhibition of human SAS cell growth in a cell viability assay, IC50=13.3081 μM	SANGER
human SBC-1 cell		Growth inhibition assay		Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=28.3507 μM	SANGER
human SCC-25 cell		Growth inhibition assay		Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=6.08656 μM	SANGER
human SK-CO-1 cell		Growth inhibition assay		Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=21.8872 μM	SANGER
human SK-MEL-3 cell		Growth inhibition assay		Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=10.0964 μM	SANGER
human ST486 cell		Growth inhibition assay		Inhibition of human ST486 cell growth in a cell viability assay, IC50=25.7464 μM	SANGER
human SW48 cell		Growth inhibition assay		Inhibition of human SW48 cell growth in a cell viability assay, IC50=24.6546 μM	SANGER
human SW780 cell		Growth inhibition assay		Inhibition of human SW780 cell growth in a cell viability assay	SANGER
human TCCSUP cell		Growth inhibition assay		Inhibition of human TCCSUP cell growth in a cell viability assay, IC50=24.7232 μM	SANGER
LNCaP cells		Function assay		Inhibition of [3H]-DHT binding to T877A androgen receptor of LNCaP cells, Ki=35 nM	15603960
MDA453 cells		Function assay		Displacement of [3H]DHT from human androgen receptor in MDA453 cells, Ki=64 nM	18291644
monkey COS7 cells		Function assay		Binding affinity to human androgen receptor expressed in monkey COS7 cells by whole cell binding assay, Ki=0.151 μM	18442912

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00298155	Cancer Prosta... 展开 >>te Neoplasms 收起 <<	Phase 2	Completed	-	United States, Washington ... 展开 >> Veterans' Administration Puget Sound Health Care System (VAPSHCS) Seattle, Washington, United States, 98108-1532 University of Washington Seattle, Washington, United States, 98195-6158 收起 <<
NCT00298155	-		Completed	-	-
NCT02064036	Adenocarcinoma of the Prostate	Not Applicable	Recruiting	October 2018	United States, California ... 展开 >> UC Davis Sacramento Cancer Center Dept of Radiation Oncology Recruiting Sacramento, California, United States, 95817 Contact: Richard Valicenti, MD 916-724-8295 rkvalicenti@ucdavis.edu Principal Investigator: Richard Valicenti, MD 收起 <<
NCT00567580	Prostate Cancer	Phase 3	Active, not recruiting	December 2025	-
NCT00769795	Prostate Cancer	Phase 2	Completed	-	United States, Washington ... 展开 >> Virginia Mason Medical Center Seattle, Washington, United States, 98101 Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 University of Washington Medical Center Seattle, Washington, United States, 98195 收起 <<
NCT02346578	Castration-resistant Prostate ... 展开 >>Cancer 收起 <<	Phase 2	Active, not recruiting	March 2020	Japan ... 展开 >> Osaka City University Graduate School of Medicine Osaka, Japan 收起 <<
NCT01120262	-		Completed	-	-
NCT02615223	Stage IV Prostate Cancer	Not Applicable	Unknown	December 2018	China, Tianjin ... 展开 >> Tianjin Medical University Cancer Institute and Hospital Recruiting Tianjin, Tianjin, China, 300060 Contact: Zhi Guo, PhD 02223340123 ext 1095 cjr.guozhi@vip.163.com Contact: Tongguo Si, PhD 02223340123 ext 1095 sitg77@163.com 收起 <<
NCT00004124	-		Active, not recruiting	-	-
NCT03119857	Prostatic Neoplasms	Phase 3	Active, not recruiting	December 2023	Denmark ... 展开 >> Copenhagen University hospital, Rigshospitalet Copenhagen, Denmark Finland Kuopio University Hospital Kuopio, Kuopio Kuopio, Finland, 70211 Turku University Hospital Turku, Finland, 20521 Netherlands Erasmus Medical Center Rotterdam Rotterdam, Netherlands, 3015 CE Sweden Sahlgrenska University Hospital Göteborg, Sweden, 41345 收起 <<
NCT00536653	Osteoporosis	Not Applicable	Completed	-	United Kingdom ... 展开 >> Wirral University Hospitals NHS Trust Upton, Wirral, Merseyside, United Kingdom, CH48 5PE 收起 <<
NCT00514917	Prostatic Neoplasms	Phase 3	Terminated(Company decision to... 展开 >> discontinue the study, not due to any safety or efficacy concerns) 收起 <<	-	United States, New Jersey ... 展开 >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Belgium Sanofi-Aventis Administrative Office Diegem, Belgium Canada Sanofi-Aventis Administrative Office Laval, Canada Czech Republic Sanofi-Aventis Administrative Office Praha, Czech Republic Germany Sanofi-Aventis Administrative Office Frankfurt, Germany Lithuania Sanofi-Aventis Administrative Office Vilnius, Lithuania Poland Sanofi-Aventis Administrative Office Warsaw, Poland Slovakia Sanofi-Aventis Administrative Office Bratislava, Slovakia Spain Sanofi-Aventis Administrative Office Barcelona, Spain 收起 <<
NCT00514917	-		Terminated(Company decision to... 展开 >> discontinue the study, not due to any safety or efficacy concerns) 收起 <<	-	-
NCT01342367	Prostate Cancer	Not Applicable	Recruiting	April 2019	United States, Illinois ... 展开 >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Fauzia Arif farif@radonc.uchicago.edu 收起 <<
NCT02716974	Prostate Cancer	Phase 2	Recruiting	March 2021	United States, District of Col... 展开 >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Channing Paller, MD 202-660-6500 cpaller1@jhmi.edu United States, Maryland Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21205 Johns Hopkins Bayview Medical Center Recruiting Baltimore, Maryland, United States, 21224 Contact: Christian Pavlovich, MD 410-550-3338 cpavlov2@jhmi.edu 收起 <<
NCT00666666	Adenocarcinoma of the Prostate... 展开 >> Stage IV Prostate Cancer 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT02918968	Prostate Cancer	Phase 4	Active, not recruiting	March 2020	Japan ... 展开 >> Site JP00024 Aichi, Japan Site JP00025 Aichi, Japan Site JP00010 Chiba, Japan Site JP00053 Chiba, Japan Site JP00038 Ehime, Japan Site JP00039 Fukuoka, Japan Site JP00040 Fukuoka, Japan Site JP00050 Fukuoka, Japan Site JP00051 Fukuoka, Japan Site JP00005 Gunma, Japan Site JP00043 Gunma, Japan Site JP00045 Gunma, Japan Site JP00035 Hiroshima, Japan Site JP00001 Hokkaido, Japan Site JP00002 Hokkaido, Japan Site JP00048 Hokkaido, Japan Site JP00054 Hokkaido, Japan Site JP00055 Ibaraki, Japan Site JP00019 Kanagawa, Japan Site JP00020 Kanagawa, Japan Site JP00021 Kanagawa, Japan Site JP00044 Kanagawa, Japan Site JP00026 Kyoto, Japan Site JP00006 Nagano, Japan Site JP00008 Nagano, Japan Site JP00041 Nagasaki, Japan Site JP00046 Nara, Japan Site JP00033 Okayama, Japan Site JP00027 Osaka, Japan Site JP00028 Osaka, Japan Site JP00029 Osaka, Japan Site JP00030 Osaka, Japan Site JP00031 Osaka, Japan Site JP00032 Osaka, Japan Site JP00042 Saga, Japan Site JP00009 Saitama, Japan Site JP00022 Shizuoka, Japan Site JP00049 Tochigi, Japan Site JP00037 Tokushima, Japan Site JP00011 Tokyo, Japan Site JP00013 Tokyo, Japan Site JP00014 Tokyo, Japan Site JP00016 Tokyo, Japan Site JP00017 Tokyo, Japan Site JP00018 Tokyo, Japan Site JP00052 Toyama, Japan Site JP00034 Yamaguchi, Japan 收起 <<
NCT00666666	-		Completed	-	-
NCT01642732	Prostate Cancer	Phase 1	Terminated(Lack of accrual and... 展开 >> funding expires in June, 2014.) 收起 <<	-	United States, District of Col... 展开 >>umbia Georgetown University Washington, D.C., District of Columbia, United States, 20057 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 收起 <<
NCT01642732	-		Terminated(Lack of accrual and... 展开 >> funding expires in June, 2014.) 收起 <<	-	-
NCT00702923	Prostate Cancer	Phase 1	Terminated(Enrollment was halt... 展开 >>ed prematurely due to slow accrual.) 收起 <<	-	United States, Wisconsin ... 展开 >> University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 收起 <<
NCT00684905	Prostate Cancer	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 收起 <<
NCT00943956	Prostate Cancer	Phase 1	Completed	-	France ... 展开 >> Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Montpellier, France, 34298 收起 <<
NCT00021450	Prostate Cancer	Phase 3	Completed	-	Belgium ... 展开 >> Academisch Ziekenhuis der Vrije Universiteit Brussel Brussels, Belgium, 1090 Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Cyprus Bank Of Cyprus Oncology Centre Nicosia, Cyprus, 2006 Strovolos Czech Republic Charles University Hospital Hradec Kralove, Czech Republic, 500 05 France Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz Besancon, France, 25030 Centre de Lutte Contre le Cancer Georges-Francois Leclerc Dijon, France, 21079 CHU de Grenoble - Hopital de la Tronche Grenoble, France, 38043 Centre Paul Strauss Strasbourg, France, 67085 Centre d'Oncologie Saint-Yves Vannes, France, 56001 Ireland Saint Luke's Hospital Dublin, Ireland, 6 Italy Spedali Civili di Brescia Brescia, Italy, 25124 Istituto Nazionale per la Ricerca sul Cancro Genoa, Italy, 16132 Luxembourg Hopital de la Ville D'Esch-sur-Alzette Esch-sur-Alzette, Luxembourg, L-4240 Netherlands Arnhems Radiotherapeutisch Instituut Arnhem, Netherlands, 6815 AD University Medical Center Groningen Groningen, Netherlands, 9700 RB Dr. Bernard Verbeeten Instituut Tilburg, Netherlands, 5042 SB Poland Medical University of Gdansk Gdansk, Poland, 80-211 Spain Institut Catala d'Oncologia - Hospital Duran i Reynals Barcelona, Spain, 08907 United Kingdom Belfast City Hospital Trust Incorporating Belvoir Park Hospital Belfast, Northern Ireland, United Kingdom, BT8 8JR 收起 <<
NCT00004124	Prostate Cancer	Phase 3	Active, not recruiting	June 1, 2022	-
NCT00349557	Prostate Cancer	Phase 2	Completed	-	United States, Washington ... 展开 >> Virginia Mason Medical Center Seattle, Washington, United States, 98101 收起 <<
NCT00067015	Prostate Cancer	Phase 3	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00014586	Prostate Cancer	Phase 3	Terminated(low accrual)	-	Germany ... 展开 >> Center of Operative Urology Bremen Bremen, Germany, D-28277 收起 <<
NCT00702923	-		Terminated(Enrollment was halt... 展开 >>ed prematurely due to slow accrual.) 收起 <<	-	-
NCT01415778	Healthy	Phase 1	Completed	-	-
NCT02085252	Prostate Cancer	Phase 3	Completed	-	France ... 展开 >> Tenon Hospital Paris France Paris, France, 75020 Ouzid, Paris La Défense, Paris, France, 92977 收起 <<
NCT00924807	Prostate Cancer	Phase 1 Phase 2	Terminated(Sponsor closed the ... 展开 >>trial) 收起 <<	-	United States, New York ... 展开 >> St.Luke's-Roosevelt Hospital Center New York, New York, United States, 10019 收起 <<
NCT00319787	Locally Advanced Prostate Canc... 展开 >>er 收起 <<	Phase 2	Completed	-	Norway ... 展开 >> Research Site Moelv, Norway Research Site Oslo, Norway Research Site Trondheim, Norway 收起 <<
NCT00255268	Metastatic Prostate Cancer	Phase 4	Withdrawn	-	Mexico ... 展开 >> Research Site Metepec, Mexico Research Site Mexico City, Mexico 收起 <<
NCT01020305	Prostate Cancer ... 展开 >> Prostatic Neoplasms Castrate-resistant Prostate Cancer (CRPC) Androgen-insensitive Prostate Cancer Hormone-refractory Prostate Cancer Metastatic Disease 收起 <<	Phase 1 Phase 2	Terminated(Decision by funding... 展开 >> sponsor due to poor accrual) 收起 <<	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT02582749	Prostate Cancer ... 展开 >> Bone Metastases Prostate Neoplasms 收起 <<	Phase 2	Active, not recruiting	January 2020	United States, Arizona ... 展开 >> University of Arizona Cancer Center at Dignity Health St. Joseph's Phoenix, Arizona, United States, 85004 United States, Illinois Illinois CancerCare, P. C. Peoria, Illinois, United States, 61615 United States, Indiana Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 IU Health Central Indiana Cancer Centers Indianapolis, Indiana, United States, 46219 United States, Iowa University of Iowa Hopital and Clinics Iowa City, Iowa, United States, 52242 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Henry Ford Hospital Detroit, Michigan, United States, 48202 Metro Health Cancer Center Wyoming, Michigan, United States, 49519 United States, Nebraska GU Research Network, LLC Omaha, Nebraska, United States, 68130 United States, New York Integrated Medical Professionals, PLLC Lake Success, New York, United States, 11042 United States, Texas University of Texas Medical Branch at Galveston Galveston, Texas, United States, 77555 United States, Wisconsin Clement J. Zablocki VA Medical Center Milwaukee, Wisconsin, United States, 53295 收起 <<
NCT01020305	-		Terminated(Decision by funding... 展开 >> sponsor due to poor accrual) 收起 <<	-	-
NCT00470834	Neoplasms, Prostate	Phase 4	Completed	-	-
NCT00470834	-		Completed	-	-
NCT00919477	-		Completed	-	-
NCT01120236	Prostate Adenocarcinoma ... 展开 >> Recurrent Prostate Carcinoma Stage IV Prostate Cancer 收起 <<	Phase 2	Completed	-	-
NCT01120236	-		Completed	-	-
NCT00188708	Prostatic Neoplasms	Phase 2	Active, not recruiting	April 2019	Canada, Ontario ... 展开 >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00924807	-		Terminated(Sponsor closed the ... 展开 >>trial) 收起 <<	-	-
NCT00688532	-		Completed	-	-
NCT00421694	Prostate Cancer	Phase 2 Phase 3	Completed	-	Italy ... 展开 >> University of L'Aquila L'Aquila, Abruzzo, Italy, 67100 收起 <<
NCT00418080	Prostate Cancer	Phase 2	Completed	-	Italy ... 展开 >> University of L'Aquila L'Aquila, Abruzzo, Italy, 67100 收起 <<
NCT00293696	Prostate Cancer	Phase 4	Completed	-	Finland ... 展开 >> TUCH Tampere, Finland, 33521 收起 <<
NCT02382094	Prostate Cancer	Phase 3	Completed	-	-
NCT00233610	Prostate Cancer	Phase 3	Completed	-	Italy ... 展开 >> Research Site Bari, BA, Italy Research Site Bologna, BO, Italy Research Site Catania, CT, Italy Research Site Bagno a Ripoli, FI, Italy Research Site Firenze, FI, Italy Research Site Genova, GE, Italy Research Site Pisa, PI, Italy Research Site Parma, PR, Italy Research Site Udine, UD, Italy Research Site Como, Italy Research Site Roma, Italy 收起 <<
NCT00637871	Gynaecomastia ... 展开 >> Prostate Cancer 收起 <<	Phase 2	Completed	-	-
NCT03358563	Prostate Cancer	Early Phase 1	Recruiting	January 2020	United States, Wisconsin ... 展开 >> University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 800-622-8922 cancerconnect@uwcarbone.wisc.edu Principal Investigator: Christos Kyriakopoulos, MD 收起 <<
NCT00672282	Non-Metastatic Prostate Cancer	Phase 3	Completed	-	-
NCT00430235	Adenocarcinoma of the Prostate	Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 收起 <<
NCT00833248	Prostate Cancer	Phase 3	Completed	-	-
NCT00086736	Prostate Cancer	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3300 收起 <<
NCT00659438	Prostate Cancer	Phase 2	Completed	-	France ... 展开 >> Research Site Bordeaux Cedex, France Research Site Creteil, France Research Site Paris, France Research Site Reims Cedex, France Research Site Villejuif, France 收起 <<
NCT00659438	-		Completed	-	-
NCT00884273	-		Completed	-	-
NCT00012090	Fallopian Tube Cancer ... 展开 >> Ovarian Cancer Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00831233	Prostate Cancer	Phase 3	Terminated(Poor recruitment du... 展开 >>e to rare targeted population) 收起 <<	-	Germany ... 展开 >> Facharztpraxis für Urologie Bamberg, Germany, 96047 Gemeinschaftspraxis Borken, Germany, 46325 Universitätsklinikum Dresden Dresden, Germany, 01307 Euromed Clinic Fürth, Germany, 90763 Urologische Gemeinschaftspraxis Hamburg, Germany, 22399 Gemeinschaftspraxis Köln, Germany, 50667 VITURO Gesellschaft für Klinische Studien Leipzig, Germany, 04109 Klinikum Offenbach GmbH Offenbach, Germany, 63069 Urologische Klinik Planegg Planegg, Germany, 82152 Wuppertaler Gemeinschaftspraxis Wuppertal, Germany, 42103 Spain Hospital Universitario Principe de Asturias Alcalá de Henares-Madrid, Spain, 28805 Fundacion Hospital Alcorcón Alcorcon, Spain, 28922 Fundación Puigvert Barcelona, Spain, 08025 Hospital de Basurto Bilbao (Bizkaia), Spain, 48013 Complejo Hospitalario Universitario A Coruña Coruña, Spain Hospital universitario Ramón y Cajal Madrid, Spain, 28034 Hospital Clinico Universitario S. Carlos Madrid, Spain, 28040 Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 28222 Hospital Manacor Manacor, Spain, 07500 Hospital Universitario Central de Asturias Oviedo, Spain, 33006 Hospital Santiago de Compostela Santiago de Compostela, Spain, 15706 Hospital Virgen Macarena Sevilla, Spain, 41014 Hospital Xeral de Vigo Vigo, Spain, 36204 United Kingdom United Bristol Healthcare NHSTrust Bristol Royal Infirmary Bristol, United Kingdom, BS2 8HW Falkirk and District Royal Infirmary Falkirk, United Kingdom, FK1 5QE Southern General Hospital Glasgow, United Kingdom, G51 4TF Castle Hill Hospital Hull, United Kingdom, HU16 5JQ Whipps Cross University Hospital London, United Kingdom, E11 1NR The Royal Free Hospital London, United Kingdom, NW3 2QG King's College Hospital London, United Kingdom, SE5 9RS Derriford Hospital Plymouth, United Kingdom, PL6 8DH Royal Hallamshire Hospital, Sheffield South Sheffield, United Kingdom, S10 2JF Sunderland Royal Hospital Sunderland, United Kingdom, SR4 7TP 收起 <<
NCT00777959	Prostate Cancer	Phase 2	Completed	-	-
NCT01658527	Prostate Cancer	Phase 2	Withdrawn(Pharmaceutical compa... 展开 >>ny has terminated orteronel (TAK-700) development for Prostate Cancer) 收起 <<	January 2017	Belgium ... 展开 >> Onze Lieve Vrouw Ziekenhuis Aals, Belgium Cliniques Universitaires Saint-Luc Brussels, Belgium AZ Groeninge Kortrijk - Campus Vercruysselaan Kortrijck, Belgium CHU Dinant Godinne - UCL Namur Yvoir, Belgium 收起 <<
NCT00554086	Prostate Cancer	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 收起 <<
NCT00590213	Prostate Cancer	Phase 4	Completed	-	Turkey ... 展开 >> Research Site Adana, Turkey Research Site Ankara, Turkey Research Site Diyarbak?r, Turkey Research Site Edirne, Turkey Research Site Eskisehir, Turkey Research Site Istanbul, Turkey Research Site Izmir, Turkey Research Site Manisa, Turkey Research Site Samsun, Turkey 收起 <<
NCT00831233	-		Terminated(Poor recruitment du... 展开 >>e to rare targeted population) 收起 <<	-	-
NCT03520478	Prostate Cancer ... 展开 >> Hormone-Dependent Prostate Cancer 收起 <<	Phase 3	Recruiting	April 30, 2025	China ... 展开 >> Ye Dingwei Recruiting Shanghai, China Contact: Dingwei Ye, Doctor 收起 <<
NCT00878436	Prostate Cancer ... 展开 >> Prostatic Neoplasms 收起 <<	Phase 1 Phase 2	Completed	-	United States, New Jersey ... 展开 >> The Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York North Shore University Hospital-Monter Cancer Center Lake Success, New York, United States, 11042 NYU Cancer Center New York, New York, United States, 10016 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 收起 <<
NCT00833248	-		Completed	-	-
NCT01416883	Healthy	Phase 1	Terminated	-	-
NCT00841113	Prostate Cancer	Phase 3	Completed	-	-
NCT00673205	Non-Metastatic Prostate Cancer	Phase 3	Completed	-	-
NCT02058706	Adenocarcinoma of the Prostate... 展开 >> Recurrent Prostate Cancer Stage IV Prostate Cancer 收起 <<	Phase 2	Active, not recruiting	December 31, 2018	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00636259	-		-	-	-
NCT00878436	-		Completed	-	-
NCT00486642	Hormone-Resistant Prostate Can... 展开 >>cer Recurrent Prostate Carcinoma 收起 <<	Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario, Canada, K1H 8L6 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00685633	Prostate Cancer	Phase 2	Withdrawn	-	-
NCT00486642	-		Completed	-	-
NCT00959335	Prostate Cancer ... 展开 >> Hirsutism 收起 <<	Phase 1	Completed	-	-
NCT01050842	Prostate Cancer ... 展开 >> Adenocarcinoma of the Prostate Hormone-resistant Prostate Cancer Stage IV Prostate Cancer 收起 <<	Early Phase 1	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic In Arizona Scottsdale, Arizona, United States, 85259 收起 <<
NCT00031889	Prostate Cancer	Phase 2	Completed	-	Switzerland ... 展开 >> Kantonspital Aarau Aarau, Switzerland, 5001 University Hospital Basel, Switzerland, CH-4031 Inselspital, Bern Bern, Switzerland, CH-3010 Spitalzentrum Biel Biel, Switzerland, CH-2500 Kantonsspital Bruderholz Bruderholz, Switzerland, CH-4101 Ratisches Kantons und Regionalspital Chur, Switzerland, CH-7000 Clinique De Genolier Genolier, Switzerland, Ch-1272 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Istituto Oncologico della Svizzera Italiana Lugano, Switzerland, CH-6900 Ospedale Beata Vergine Mendrisio, Switzerland, CH-6850 Institut Central des Hopitaux Valaisans Sion, Switzerland, CH1951 Universitaetsspital Zurich, Switzerland, CH-8091 收起 <<
NCT01200810	Adenocarcinoma of the Prostate... 展开 >> Recurrent Prostate Cancer Stage IV Prostate Cancer 收起 <<	Phase 2	Terminated(Drug was no longer ... 展开 >>available) 收起 <<	-	United States, New Jersey ... 展开 >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 收起 <<
NCT00884273	Prostate Cancer	Phase 3	Completed	-	-
NCT00002874	Prostate Cancer	Phase 3	Active, not recruiting	-	-
NCT01200810	-		Terminated(Drug was no longer ... 展开 >>available) 收起 <<	-	-
NCT00002874	-		Active, not recruiting	-	-
NCT00657904	Non-metastatic Prostate Cancer	Phase 3	Completed	-	-
NCT01039233	Bioequivalency	Phase 1	Completed	-	Canada, Quebec ... 展开 >> SFBC Anapharm Montreal, Quebec, Canada, H3X 2H9 收起 <<
NCT00871585	-		Completed	-	Croatia ... 展开 >> Research Site Cakovec, Croatia Research Site Dubrovnik, Croatia Research Site Karlovac, Croatia Research Site Pula, Croatia Research Site Rijeka, Croatia Research Site Sibenik, Croatia Research Site Sisak, Croatia Research Site Slavonski brod, Croatia Research Site Split, Croatia Research Site Vinkovci, Croatia Research Site Virovitica, Croatia Research Site Vukovar, Croatia Research Site Zabok, Croatia Research Site Zadar, Croatia Research Site Zagreb, Croatia 收起 <<
NCT00468715	Breast Cancer	Phase 2	Active, not recruiting	March 2019	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, District of Columbia Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Massachusetts Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 United States, New York Ralph Lauren Center for Cancer Care and Prevention New York, New York, United States, 10035 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Duke Cancer Institute Durham, North Carolina, United States, 27710 收起 <<
NCT00094328	Puberty, Precocious	Phase 2	Completed	-	United States, Alabama ... 展开 >> Research Site Birmingham, Alabama, United States, 35233 United States, Florida Research Site Jacksonville, Florida, United States, 32207 United States, Indiana Research Site Indianapolis, Indiana, United States, 46202 United States, Minnesota Research Site Minneapolis, Minnesota, United States, 55416 United States, Oklahoma Research Site Tulsa, Oklahoma, United States, 74136 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19134 United States, South Carolina Research Site Greenville, South Carolina, United States, 29615 United States, Texas Research Site Temple, Texas, United States, 76508 United States, Washington Research Site Spokane, Washington, United States, 99204 Canada, Ontario Research Site London, Ontario, Canada, N6A 4G5 France Research Site Montpellier Cedex, France, 34295 India Research Site Chennai, India, 600020 Research Site New Dehli, India, 110029 Russian Federation Research Site Moscow, Russian Federation, 117036 United Kingdom Research Site London, United Kingdom, WC1N 3JH 收起 <<
NCT00757692	Prostate Cancer	Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BC Cancer Agency - Centre for Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 收起 <<
NCT00960310	Prostate Cancer ... 展开 >> Hirsutism 收起 <<	Phase 1	Completed	-	-
NCT03147196	Stage I Prostate Adenocarcinom... 展开 >>a Stage II Prostate Adenocarcinoma 收起 <<	Phase 2	Recruiting	June 2022	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office 855-776-0015 Mangskau.Toni@mayo.edu Principal Investigator: Erik P. Castle 收起 <<
NCT01251861	Recurrent Prostate Carcinoma ... 展开 >> Stage I Prostate Cancer AJCC v7 Stage IIA Prostate Cancer AJCC v7 Stage IIB Prostate Cancer AJCC v7 Stage III Prostate Cancer AJCC v7 收起 <<	Phase 2	Active, not recruiting	-	-
NCT01416870	Healthy	Phase 1	Terminated	-	-
NCT00094328	-		Completed	-	-
NCT00973050	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT01664923	Prostate Cancer	Phase 2	Completed	-	-
NCT01664923	-		Completed	-	-
NCT02614859	Cancer of Prostate	Phase 2	Recruiting	April 2022	United States, Maryland ... 展开 >> National Cancer Institute Recruiting Bethesda, Maryland, United States, 20892-9760 Contact: Marijo Bilusic, MD marijo.bilusic@nih.gov United States, Pennsylvania Fox Chase Cancer Center - Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19111-2497 收起 <<
NCT00972855	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT00814788	-		Completed	-	-
NCT00551044	Prostatic Neoplasms	Not Applicable	Completed	-	United Kingdom ... 展开 >> Wirral University Teaching Hospitals NHS Trust Upton, Wirral, Merseyside, United Kingdom, CH48 5PE 收起 <<
NCT03650894	Breast Neoplasm Female ... 展开 >> Breast Cancer Breast Carcinoma Breast Tumor 收起 <<	Phase 2	Not yet recruiting	October 2023	United States, Oregon ... 展开 >> Providence Oncology & Hematology Care Clinic - Eastside Not yet recruiting Portland, Oregon, United States, 97213 Sub-Investigator: Rachel Sanborn, MD Sub-Investigator: Alison Conlin, MD Sub-Investigator: Todd Crocenzi, MD Sub-Investigator: Brendan Curti, MD Sub-Investigator: John Godwin, MD Sub-Investigator: Rom Leidner, MD Sub-Investigator: Rui Li, MD, PhD Sub-Investigator: Walter Urba, MD, PhD Principal Investigator: David Page, MD Sub-Investigator: Herschel Wallen, MD Sub-Investigator: Moran Amy, PhD 收起 <<
NCT03090165	Triple Negative Breast Cancer	Phase 1 Phase 2	Recruiting	September 2019	United States, Illinois ... 展开 >> University of Illinois Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Ayesha Zaidi 312-413-1902 azaidi22@uic.edu Principal Investigator: Kent Hoskins, MD United States, Michigan Michigan State University Recruiting Lansing, Michigan, United States, 48910 Contact: Karen Luellen 517-975-9534 karen.luellen@hc.msu.edu Principal Investigator: Deimante Tamkus, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Alison Haegler 732-235-8060 agh46@cinj.rutgers.edu Principal Investigator: Nancy Chan, MD United States, Pennsylvania Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Sean Flemings 717-531-5364 sfleming1@pennstatehealth.psu.edu Principal Investigator: Cristina Truica, MD United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 608-262-5223 cancerconnect@uwcarbone.wisc.edu 收起 <<
NCT01288911	Prostatic Neoplasms	Phase 2	Completed	-	-
NCT00630344	Prostate Cancer	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00846976	Prostate Cancer	Phase 3	Completed	-	United States, New York ... 展开 >> Research Site New York, New York, United States 收起 <<
NCT01288911	-		Completed	-	-
NCT02605486	Metastatic Breast Cancer (MBC)	Phase 1 Phase 2	Recruiting	November 2020	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Ayca Gucalp, MD 646-888-4536 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Ayca Gucalp, MD 646-888-4536 收起 <<
NCT01809691	Prostate Cancer	Phase 3	Active, not recruiting	October 2027	-
NCT00866554	Prostate Cancer ... 展开 >> Erectile Dysfunction Lower Urinary Tract Symptoms 收起 <<	Phase 2	Unknown	December 2015	Canada ... 展开 >> CHUQ- Hotel-Dieu de Quebec Quebec, Canada, G1R 2J6 收起 <<
NCT01044706	-		Completed	-	-
NCT00814788	Prostate Cancer	Phase 2	Completed	-	United States, California ... 展开 >> University of California Davis Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT02910050	Breast Cancer	Phase 2	Recruiting	December 2018	China, Guangdong ... 展开 >> State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Fei Xu, MD +86-13711277870 xufei@sysucc.org.cn 收起 <<
NCT01044706	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> SFBC Anapharm sainte-Foy, Quebec, Canada, G1V 2K8 收起 <<
NCT02348281	Breast Cancer	Phase 2	Terminated(it's too slow to en... 展开 >>roll suitable patients into this study) 收起 <<	-	China ... 展开 >> Fudan University Shanghai Cancer Center Shanghai, China, 200032 收起 <<
NCT02353988	Breast Neoplasms	Phase 2	Unknown	May 2017	-
NCT02146937	Detectable Prostate Nodules	Phase 2	Withdrawn(Due to lack of accru... 展开 >>al for this study. PI decided to close the study.) 收起 <<	-	United States, Maryland ... 展开 >> Johns Hopkins Hospital Baltimore, Maryland, United States, 21205 收起 <<
NCT02697032	Breast Cancer	Phase 2	Recruiting	April 2019	Netherlands ... 展开 >> University Medical Center Groningen Recruiting Groningen, Netherlands, 9713 GZ Contact: C. P. Schröder, MD, PhD +3150 3612821 c.p.schroder@umcg.nl Contact: G. A.P. Hospers, MD, PhD +31 50 3612821 g.a.p.hospers@umcg.nl Principal Investigator: C. P. Schröder, MD, PhD 收起 <<
NCT03055312	Metastatic Triple Negative Bre... 展开 >>ast Cancer 收起 <<	Phase 3	Recruiting	December 2020	China, Guangdong ... 展开 >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Zhong-yu Yuan, MD 86-20-87342496 yuanzhy@sysucc.org.cn Contact: Yong-yi Zhong, BD 86-20-87342635 zhongyy@sysucc.org.cn Sun Yat-sen University, Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Yuan Zhong-yu, MD 86-20-87342496 yuanzhy@sysucc.org.cn Contact: Huang Jia-Jia, MD 86-20-87343794 huangjiaj@sysucc.org.cn Principal Investigator: Yuan Zhong-yu, MD Sub-Investigator: Huang Jia-Jia, MD 收起 <<
NCT00630344	-		Completed	-	-
NCT02487823	Non Castrate Metastatic Prosta... 展开 >>te Cancer 收起 <<	Phase 1	Terminated(Defect of recruitme... 展开 >>nt) 收起 <<	-	France ... 展开 >> Institut Paoli Calmettes Marseille, France, 13009 收起 <<

Bicalutamide/比卡鲁胺 {[allProObj[0].p_purity_real_show]}

Bicalutamide/比卡鲁胺纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Bicalutamide/比卡鲁胺质控信息

Bicalutamide/比卡鲁胺生物活性

Bicalutamide/比卡鲁胺细胞研究

Bicalutamide/比卡鲁胺动物研究

Bicalutamide/比卡鲁胺临床研究

Bicalutamide/比卡鲁胺参考文献

Bicalutamide/比卡鲁胺实验方案

Bicalutamide/比卡鲁胺技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Bicalutamide/比卡鲁胺 {[allProObj[0].p_purity_real_show]}

Bicalutamide/比卡鲁胺 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Bicalutamide/比卡鲁胺 质控信息

Bicalutamide/比卡鲁胺 生物活性

Bicalutamide/比卡鲁胺 细胞研究

Bicalutamide/比卡鲁胺 动物研究

Bicalutamide/比卡鲁胺 临床研究

Bicalutamide/比卡鲁胺 参考文献

Bicalutamide/比卡鲁胺 实验方案

Bicalutamide/比卡鲁胺 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Bicalutamide/比卡鲁胺纯度/质量文件产品仅供科研

Bicalutamide/比卡鲁胺质控信息

Bicalutamide/比卡鲁胺生物活性

Bicalutamide/比卡鲁胺细胞研究

Bicalutamide/比卡鲁胺动物研究

Bicalutamide/比卡鲁胺临床研究

Bicalutamide/比卡鲁胺参考文献

Bicalutamide/比卡鲁胺实验方案

Bicalutamide/比卡鲁胺技术信息